What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome.
glioblastoma
population-based
prognostic factors
survival
treatment
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
06
2023
accepted:
17
08
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
Glioblastoma is the most common and most aggressive primary brain tumor in adults. Despite multimodal treatment, the median survival time is 15-16 months and 5-year survival rate 5%-10%. The primary goal of this study was to identify prognostic factors for survival in an unselected population of patients operated for glioblastoma. The secondary goal was to explore changes in outcome and the clinical management of this patient group over time. We identified 222 consecutive adults operated for glioblastoma between November 2012 and June 2016 at the Department of Neurosurgery, Sahlgrenska University Hospital in Gothenburg, serving a health care region in the western part of Sweden with 1.900.000 inhabitants. Clinical variables were identified and tested as predictors for prognosis in extended Poisson regression models. The results were compared with a previously published cohort from 2004 to 2008, before current standard of care based on molecular tumor diagnosis was fully implemented. Median overall survival was 1.07 years, which was significantly longer than in the 2004-2008 cohort (1.07 vs. 0.73 y, age- and sex adjusted HR = 1.89, The median survival for patients with glioblastoma treated according to current standard treatment has moderately but significantly increased, with MGMT promoter hypermethylation as the strongest predictor for survival.
Sections du résumé
Background
UNASSIGNED
Glioblastoma is the most common and most aggressive primary brain tumor in adults. Despite multimodal treatment, the median survival time is 15-16 months and 5-year survival rate 5%-10%. The primary goal of this study was to identify prognostic factors for survival in an unselected population of patients operated for glioblastoma. The secondary goal was to explore changes in outcome and the clinical management of this patient group over time.
Methods
UNASSIGNED
We identified 222 consecutive adults operated for glioblastoma between November 2012 and June 2016 at the Department of Neurosurgery, Sahlgrenska University Hospital in Gothenburg, serving a health care region in the western part of Sweden with 1.900.000 inhabitants. Clinical variables were identified and tested as predictors for prognosis in extended Poisson regression models. The results were compared with a previously published cohort from 2004 to 2008, before current standard of care based on molecular tumor diagnosis was fully implemented.
Results
UNASSIGNED
Median overall survival was 1.07 years, which was significantly longer than in the 2004-2008 cohort (1.07 vs. 0.73 y, age- and sex adjusted HR = 1.89,
Conclusion
UNASSIGNED
The median survival for patients with glioblastoma treated according to current standard treatment has moderately but significantly increased, with MGMT promoter hypermethylation as the strongest predictor for survival.
Identifiants
pubmed: 37711136
doi: 10.3389/fsurg.2023.1249366
pmc: PMC10498299
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1249366Informations de copyright
© 2023 Fekete, Werlenius, Tisell, Pivodic, Smits, Jakola and Rydenhag.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Chin Med J (Engl). 2009 Jun 5;122(11):1245-9
pubmed: 19567131
J Neurosurg. 2010 May;112(5):997-1004
pubmed: 19817542
Neuro Oncol. 2023 Apr 6;25(4):631-634
pubmed: 36562460
Neuro Oncol. 2013 Jun;15(6):797-805
pubmed: 23460319
Ann Oncol. 2013 Dec;24(12):3117-23
pubmed: 24130262
World Neurosurg. 2018 Jul;115:e59-e66
pubmed: 29631083
Br J Neurosurg. 2014 Jun;28(3):351-5
pubmed: 24111708
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neurol Scand. 2010 Sep;122(3):159-67
pubmed: 20298491
Biometrics. 1980 Jun;36(2):299-305
pubmed: 7407317
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
J Neurooncol. 2019 Mar;142(1):91-101
pubmed: 30523606
J Cancer Res Clin Oncol. 2021 Nov;147(11):3381-3390
pubmed: 33743072
Neurosurgery. 2010 Aug;67(2):446-58
pubmed: 20644432
Neuro Oncol. 2019 May 6;21(5):616-627
pubmed: 30668814
Strahlenther Onkol. 2003 Jan;179(1):8-15
pubmed: 12540979
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Clin Neurol Neurosurg. 2012 Sep;114(7):840-5
pubmed: 22377333
Acta Neurochir (Wien). 2021 Jul;163(7):1895-1905
pubmed: 33742279
Neuro Oncol. 2012 Sep;14(9):1178-84
pubmed: 22869622
Clin Epigenetics. 2021 May 3;13(1):102
pubmed: 33941250
Acta Neurochir (Wien). 2007 Mar;149(3):245-52; discussion 252-3
pubmed: 17273889
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Int J Mol Sci. 2022 Jun 29;23(13):
pubmed: 35806212
Curr Opin Neurol. 2014 Dec;27(6):666-74
pubmed: 25364955
J Neurosci Rural Pract. 2013 Aug;4(Suppl 1):S46-55
pubmed: 24174800
Int J Clin Oncol. 2010 Aug;15(4):352-8
pubmed: 20232102
Acta Neurol Scand. 2016 Jun;133(6):434-41
pubmed: 26358197
Neurooncol Pract. 2014 Dec;1(4):166-171
pubmed: 26034628
J Neurooncol. 2018 Sep;139(2):479-489
pubmed: 29754199
Br J Neurosurg. 2007 Oct;21(5):496-500
pubmed: 17852105
Mod Pathol. 2022 Nov;35(11):1551-1561
pubmed: 35701666
Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76
pubmed: 18425006
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
PLoS One. 2020 Feb 13;15(2):e0228480
pubmed: 32053655
Acta Neurol Scand. 2018 Oct;138(4):332-337
pubmed: 29882211
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
Front Oncol. 2021 Dec 13;11:748691
pubmed: 34966669
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurosurgery. 2019 Jan 1;84(1):190-197
pubmed: 29617848
Acta Oncol. 2019 Mar;58(3):334-341
pubmed: 30732527
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945